Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients

Vaccine

Volumn 30, Issue 33, 2012, Pages 5009-5018

  Chang, Yu Tzu ^a,b   Guo, Chao Yu ^c   Tsai, Ming Song ^d   Cheng, Ya Yun ^b   Lin, Meng Te ^d   Chen, Chien Hui ^e   Shen, Daphne ^e   Wang, Jen Ren ^b   Sung, Junne Ming ^a,d  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d KUO GENERAL HOSPITAL   (Taiwan)

^e Adimmune Corporation   (Taiwan)

Author keywords

Hemodialysis; Immunocompromised; Non adjuvanted vaccine; Pandemic 2009 H1N1 influenza A virus

Indexed keywords

ADIMFLU S; CHOLESTEROL; HEMAGGLUTINATION INHIBITING ANTIBODY; HEMOGLOBIN; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; HEMODIALYSIS PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; PAIN; PRIORITY JOURNAL; SEROCONVERSION; SINGLE DRUG DOSE; SKIN REDNESS; SWELLING; TAIWAN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TAIWAN; VACCINATION; YOUNG ADULT;

EID: 84862764610     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.016     Document Type: Article

References (43)

1. New influenza A (H1N1) virus: global epidemiological situation. Wkly Epidemiol Rec 2009, 84(June (25)):249-257.
2. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(June (25)):2605-2615.
3. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(December (25)):2405-2413.
4. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(December (25)):2424-2435.
5. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(January (9708)):56-66.
6. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(January (9708)):41-48.
7. Marcelli D., Marelli C., Richards N. Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant 2009, 24(December (12)):3566-3572.
8. Dikow R., Eckerle I., Ksoll-Rudek D., Hampel H., Schwenger V., Zeier M., et al. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011, 57(May (5)):716-723.
9. Temiz G., Kasifoglu N., Kiris A., Ozturk S., Sahin G., Yalcin A.U., et al. Immune response after a single vaccination against 2009 influenza A H1N1 in hemodialysis patients. Ren Fail 2010, 32(July (6)):716-720.
10. Labriola L., Hombrouck A., Marechal C., Van Gucht S., Brochier B., Thomas I., et al. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant 2011, 26(April (4)):1424-1428.
11. Broeders N.E., Hombrouck A., Lemy A., Wissing K.M., Racape J., Gastaldello K., et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol 2011, 6(November (11)):2573-2578.
12. Crespo M., Collado S., Mir M., Cao H., Barbosa F., Serra C., et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol 2011, 6(September (9)):2208-2214.
13. Beaudreuil S., Krivine A., Hebibi H., Ducot B., Mazet A.A., Taouffik Y., et al. Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients. Hum Vaccin 2011, 7(August (8)).
14. Dunne N., Stratford J., Jones L., Sohampal J., Robertson R., Booth M.I., et al. Anatomical failure following laparoscopic antireflux surgery (LARS): does it really matter?. Ann R Coll Surg Engl 2010, 92(March (2)):131-135.
15. Summary of the European Public Assessment Report (EPAR) for Focetria. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/000710/human_med_000796.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d124.
16. Product Information Leaflet Arepanrix™ H1N1 AS03-adjuvanted H1N1 pandemic influenza vaccine - Version 4 approved 20 April 2010. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-eng.php.
17. European Committee for Proprietary Medicinal Products Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) 1997, European Agency for the Evaluation of Medicinal Products, London.
18. Center for Biologics Evaluation and Research Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007, Food and Drug Administration, Bethesda, MD.
19. Kung H.C., Huang K.C., Kao T.M., Lee Y.C., Chang F.Y., Wang N.C., et al. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine 2010, 28(October (45)):7337-7343.
20. Chi C.Y., Liu C.C., Lin C.C., Wang H.C., Cheng Y.T., Chang C.M., et al. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010, 17(December (12)):1958-1962.
21. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004, 24(August (8)):1329-1330.
22. Guidance for Industry Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Available from: . http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm.
23. Ott U., Sauerbrei A., Lange J., Schafler A., Walther M., Wolf G., et al. Serological response to influenza A H1N1 vaccine (Pandemrix((R))) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol 2012, (February). [Epub ahead of print].
24. Lertdumrongluk P., Changsirikulchai S., Limkunakul C., Prachukthum P., Punpiput P., Buppanharun R., et al. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine 2012, 30(February (6)):1108-1114.
25. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70(December (4)):767-777.
26. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(April (4)):937-943.
27. Meyer S., Adam M., Schweiger B., Ilchmann C., Eulenburg C., Sattinger E., et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011, 91(May (9)):1031-1035.
28. Burlington D.B., Wright P.F., van Wyke K.L., Phelan M.A., Mayner R.E., Murphy B.R. Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985, 21(May (5)):847-849.
29. Ortqvist A., Berggren I., Insulander M., de Jong B., Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 2011, 52(May (10)):1203-1211.
30. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(November (20)):1945-1952.
31. Chen H., Wang Y., Liu W., Zhang J., Dong B., Fan X., et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis 2009, 15(November (11)):1849-1850.
32. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460(August (7258)):1021-1025.
33. Tang J.W., Tambyah P.A., Wilder-Smith A., Puong K.Y., Shaw R., Barr I.G., et al. Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis 2010, 16(May (5)):874-876.
34. Katz J., Hancock K., Veguilla V., Zhong W., Lu X.H., Sun H., et al. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine (reprinted from MMWR, vol. 58, pp 521-524, 2009). J Am Med Assoc 2009 Jul, 302(3):249-250.
35. Antonen J.A., Hannula P.M., Pyhala R., Saha H.H., Ala-Houhala I.O., Pasternack A.I. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000, 86(September (1)):56-61.
36. Scharpe J., Peetermans W.E., Vanwalleghem J., Maes B., Bammens B., Claes K., et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis 2009, 54(July (1)):77-85.
37. Girndt M., Sester M., Sester U., Kaul H., Kohler H. Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl 2001, 78(February):S206-S211.
38. Sester U., Sester M., Hauk M., Kaul H., Kohler H., Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000, 15(August (8)):1217-1223.
39. Yoon J.W., Gollapudi S., Pahl M.V., Vaziri N.D. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006, 70(July (2)):371-376.
40. Eleftheriadis T., Antoniadi G., Liakopoulos V., Kartsios C., Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20(September-October (5)):440-451.
41. Contin C., Pitard V., Delmas Y., Pelletier N., Defrance T., Moreau J.F., et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology 2003, 110(September (1)):131-140.
42. Hak L.J., Leffell M.S., Lamanna R.W., Teasley K.M., Bazzarre C.H., Mattern W.D. Reversal of skin test anergy during maintenance hemodialysis by protein and calorie supplementation. Am J Clin Nutr 1982, 36(December (6)):1089-1092.
43. Hassan K., Shternberg L., Alhaj M., Giron R., Reshef R., Barak M., et al. The effect of erythropoietin therapy and hemoglobin levels on the immune response to Engerix-B vaccination in chronic kidney disease. Ren Fail 2003, 25(May (3)):471-478.